FDA considers adding a dozen peptides to its bulk drug compounding list RAPS When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions Peptides in 2026, What the FDA Review Means Olympia Pharmaceuticals peptides #fda #longevity #glp1 #precisionmedicine #compounding Katherine Erickson The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what Mark your calendar. July 23 24. FDA advisory committee reviewing BPC 157, TB 500, MOTS C, semax, epitalon, KPV, and DSIP for the 503A compounding list. The peptide landscape could shift significantly.